Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. - Wikidata - awgldk - TriplyDB

Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.

Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.

http://www.wikidata.org/entity/Q34729962

about

Perspectives for therapeutic HPV vaccine development Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine Moving forward with human papillomavirus immunotherapies.Recent advances in understanding and preventing human papillomavirus-related disease.An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia.Current state in the development of candidate therapeutic HPV vaccines Virucide properties of cold atmospheric plasma for future clinical applications.The current state of therapeutic and T cell-based vaccines against human papillomaviruses.Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine.Targeting Persistent Human Papillomavirus Infection.CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer.Therapeutic vaccines for high-risk HPV-associated diseases.Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins.Targeting Head and Neck Cancer by Vaccination.Vaccinations for Anal Squamous Cancer: Current and Emerging Therapies

P2860

Q28069272-E7ECC14A-5251-4F72-80AF-B4BAF18332E3 Q37224420-49C127F0-611A-4020-8643-276399095D0E Q37473299-A9938112-7D5A-46B7-9D31-D40F7B49504A Q37709706-17B5247E-3AA7-4A22-B8E5-E56954245710 Q38386055-A866ED1F-E7D4-4AF6-B6B8-6BFF8CBCD84A Q38743922-02E9CE2B-D4EC-4805-978F-B3D4488AF88A Q38815371-C7B1CEBF-82EA-492A-9B16-E0CE5846F174 Q39033576-22853329-189E-44AC-BBDF-1CAE6D52A552 Q39044990-C4CBC4E3-4370-4007-A15B-61F06B25B116 Q40078375-E9F981BF-F7BF-45C2-93C6-0B2321E25146 Q41067857-BE031646-6A8B-4CD7-9EE9-17F271CF591A Q47255618-EB4481F5-F9BD-4479-9C02-79DC7A5DA46B Q47574658-FA4752EC-4F91-4C96-85DD-ED381A00B951 Q54217605-D788469C-EB3D-4F25-90CD-53B11612CED7 Q58548093-868EA0D4-46F8-4EA3-8713-9ED612DF5AC5

P2860

Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.

http://www.wikidata.org/entity/Q34729962

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Regression of human papillomav ...... by MVA E2 therapeutic vaccine.

@ast

Regression of human papillomav ...... by MVA E2 therapeutic vaccine.

@en

Regression of human papillomav ...... by MVA E2 therapeutic vaccine.

@nl

type

label

Regression of human papillomav ...... by MVA E2 therapeutic vaccine.

@ast

Regression of human papillomav ...... by MVA E2 therapeutic vaccine.

@en

Regression of human papillomav ...... by MVA E2 therapeutic vaccine.

@nl

prefLabel

Regression of human papillomav ...... by MVA E2 therapeutic vaccine.

@ast

Regression of human papillomav ...... by MVA E2 therapeutic vaccine.

@en

Regression of human papillomav ...... by MVA E2 therapeutic vaccine.

@nl

P1433

Q34729962-93FC27F7-2CE7-4EE5-81B5-BA8C7B0B5E75

P1476

Q34729962-1F0FB6C6-569F-475E-A089-FEBF7B54811C

P2093

Q34729962-005CA2DD-C1EB-42B1-AA63-120E612C5E8B

Q34729962-189A7F51-8802-414C-8C7B-748DE9798971

Q34729962-268DED98-D3EA-4394-8456-C43412F714D2

Q34729962-3DDA72B2-FFF0-47E9-A7F1-F272E0C07306

Q34729962-470D8C74-E887-46E2-954E-BE275651C980

Q34729962-65AC61E3-D875-4A5A-9A4B-560B944BB2C2

Q34729962-79AD4CAC-36DF-476B-9302-1E57E81A6EE3

Q34729962-88584766-61E4-4E92-80D5-7E46F4C8F124

Q34729962-A83CC315-BD7C-4E24-8F4C-B821E83E18C6

Q34729962-BA8B465C-86F3-4CD6-B560-4B90824B2CA7

P2860

Q34729962-05059ACF-88D5-4DFF-BCF7-0B30F33FEFF2

Q34729962-057841BD-88D6-4956-B78F-31F76D6CC865

Q34729962-05878AB0-834E-4CBB-80C5-8C5594068735

Q34729962-0ADEB59D-D10F-41D0-BAE0-BCEB691E7EB9

Q34729962-0AF57267-6589-4A55-884A-D7EA6AE04744

Q34729962-0F4E4531-BAF7-43BE-8137-E53EEBDEF91E

Q34729962-18B3E43A-8E4D-42FC-9D41-A73EC0CC7136

Q34729962-1906D8B9-C9A5-4839-872E-2176F70E0C28

Q34729962-1D3A07AE-AC24-4D94-85EA-8CA96FE43E72

Q34729962-23A24441-72B3-43FE-BFBB-A3F4DA08FC55

P304

Q34729962-8D2909A0-C379-47D3-B47D-4E339BF2351F

P31

Q34729962-20FD1562-C988-4945-B31B-CD02B6DE8701

P356

Q34729962-13BFC5B0-722F-4D32-9CDC-86B464C5A831

P433

Q34729962-F848B3F0-29E8-4EB2-BB1F-5924538D6EA7

P478

Q34729962-2F9B1952-C092-4471-A0A9-0C1DA6A8CFA7

P577

Q34729962-29CFAA56-D02B-4E9D-880F-D24956466059

P5875

Q34729962-8F2C09A5-87E7-44E1-8D31-C2560892C126

P698

Q34729962-77A0015B-A4E0-46CB-BA59-3DDF7015C7A5

P932

Q34729962-5B787560-82DB-49EC-AB8F-AAEFC82AE2B2

P356

P1433

Human Gene Therapy

P1476

Regression of human papillomav ...... by MVA E2 therapeutic vaccine.

@en

P2093

Antonio Ricardez-Arenas

http://www.w3.org/2001/XMLSchema#string

Armando Del Follo-Valencia

http://www.w3.org/2001/XMLSchema#string

Carlos Rosales

http://www.w3.org/2001/XMLSchema#string

Claudia Arellano-Fiore

http://www.w3.org/2001/XMLSchema#string

Freddy Villarreal

http://www.w3.org/2001/XMLSchema#string

Jose Martin Arroyo-Cazarez

http://www.w3.org/2001/XMLSchema#string

Jose-Roberto Magallanes-Molina

http://www.w3.org/2001/XMLSchema#string

Mario López-Contreras

http://www.w3.org/2001/XMLSchema#string

Miguel Angel Pirez

http://www.w3.org/2001/XMLSchema#string

Miriam Veronica Guerrero

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Surgery for cervical intraepithelial neoplasia

Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis

Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

P304

1035-1049

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/HUM.2014.024

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266571952

http://www.w3.org/2001/XMLSchema#string

P698

25275724

http://www.w3.org/2001/XMLSchema#string

P932

4270165

http://www.w3.org/2001/XMLSchema#string